Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Assessment of Alternative Treatment Strategies for Chronic Genotype 1 Hepatitis C [Internet].

Goldhaber-Fiebert JD, Barnett PG, Dally S, Asch SM, Liu S, Cipriano L, Owens DK, Miake-Lye IM, Beroes JM, Shekelle PG.

Washington (DC): Department of Veterans Affairs; 2013 Mar.

2.

A small percentage of patients with hepatitis C receive triple therapy with boceprevir or telaprevir.

Chen EY, Sclair SN, Czul F, Apica B, Dubin P, Martin P, Lee WM.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1014-20.e1-2. doi: 10.1016/j.cgh.2013.03.032. Epub 2013 Apr 16.

PMID:
23602817
3.

Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.

Bailly F, Pradat P, Virlogeux V, Zoulim F.

Dig Dis. 2015;33(4):613-23. doi: 10.1159/000375359. Epub 2015 Jul 6.

PMID:
26159282
4.

Cost effectiveness of direct-acting antiviral therapy for treatment-naive patients with chronic HCV genotype 1 infection in the veterans health administration.

Chan K, Lai MN, Groessl EJ, Hanchate AD, Wong JB, Clark JA, Asch SM, Gifford AL, Ho SB.

Clin Gastroenterol Hepatol. 2013 Nov;11(11):1503-10. doi: 10.1016/j.cgh.2013.05.014. Epub 2013 May 22.

PMID:
23707354
5.

Boceprevir and telaprevir-based regimens for the treatment of hepatitis C virus in HIV/HCV coinfected patients.

Beste LA, Green PK, Ioannou GN.

Eur J Gastroenterol Hepatol. 2015 Feb;27(2):123-9. doi: 10.1097/MEG.0000000000000241.

PMID:
25503739
6.

Uptake and utilization of directly acting antiviral medications for hepatitis C infection in U.S. veterans.

Gidwani R, Barnett PG, Goldhaber-Fiebert JD, Asch SM, Lo J, Dally SK, Owens DK.

J Viral Hepat. 2015 May;22(5):489-95. doi: 10.1111/jvh.12344. Epub 2014 Nov 24.

7.

Hepatitis C virus NS3 protease genotyping and drug concentration determination during triple therapy with telaprevir or boceprevir for chronic infection with genotype 1 viruses, southeastern France.

Aherfi S, Solas C, Motte A, Moreau J, Borentain P, Mokhtari S, Botta-Fridlund D, Dhiver C, Portal I, Ruiz JM, Ravaux I, Bregigeon S, Poizot-Martin I, Stein A, Gérolami R, Brouqui P, Tamalet C, Colson P.

J Med Virol. 2014 Nov;86(11):1868-76. doi: 10.1002/jmv.24016. Epub 2014 Jul 23.

PMID:
25052594
8.

Telaprevir: changing the standard of care of chronic hepatitis C.

Rajani AK, Ravindra BK, Dkhar SA.

J Postgrad Med. 2013 Jan-Mar;59(1):42-7. doi: 10.4103/0022-3859.109493. Review.

9.

Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).

Deuffic-Burban S, Schwarzinger M, Obach D, Mallet V, Pol S, Pageaux GP, Canva V, Deltenre P, Roudot-Thoraval F, Larrey D, Dhumeaux D, Mathurin P, Yazdanpanah Y.

J Hepatol. 2014 Jul;61(1):7-14. doi: 10.1016/j.jhep.2014.03.011. Epub 2014 Mar 17.

PMID:
24650691
10.

Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting.

Mandorfer M, Payer BA, Niederecker A, Lang G, Aichelburg MC, Strassl R, Boesecke C, Rieger A, Trauner M, Peck-Radosavljevic M, Reiberger T.

AIDS Patient Care STDS. 2014 May;28(5):221-7. doi: 10.1089/apc.2013.0359.

PMID:
24796757
11.

Early virologic responses and hematologic safety of direct-acting antiviral therapies in veterans with chronic hepatitis C.

Belperio PS, Hwang EW, Thomas IC, Mole LA, Cheung RC, Backus LI.

Clin Gastroenterol Hepatol. 2013 Aug;11(8):1021-7. doi: 10.1016/j.cgh.2013.03.006. Epub 2013 Mar 21.

PMID:
23524130
12.

Safety and efficacy of protease inhibitors to treat hepatitis C after liver transplantation: a multicenter experience.

Coilly A, Roche B, Dumortier J, Leroy V, Botta-Fridlund D, Radenne S, Pageaux GP, Si-Ahmed SN, Guillaud O, Antonini TM, Haïm-Boukobza S, Roque-Afonso AM, Samuel D, Duclos-Vallée JC.

J Hepatol. 2014 Jan;60(1):78-86. doi: 10.1016/j.jhep.2013.08.018. Epub 2013 Aug 29.

PMID:
23994384
13.

[Direct antiviral treatment strategies in chronic hepatitis C].

Neumann-Haefelin C, Blum HE, Thimme R.

Dtsch Med Wochenschr. 2012 Jun;137(25-26):1360-5. doi: 10.1055/s-0032-1305064. Epub 2012 May 31. Review. German.

PMID:
22653493
14.

A population approach to disease management: hepatitis C direct-acting antiviral use in a large health care system.

Belperio PS, Backus LI, Ross D, Neuhauser MM, Mole LA.

J Manag Care Spec Pharm. 2014 Jun;20(6):533-40.

15.

[Israeli guidelines for the treatment of chronic hepatitis C infection--2012 Israeli Association for the Study of the Liver].

Zuckerman E, Safadi R, Oren R, Shibolet O, Baruch Y, Bruck R, Lurei Y, Kaspa RT, Abu-Mouch S, Shouval D, Ben-Ari Z; Israeli Association for the Study of the Liver.

Harefuah. 2012 Dec;151(12):709-14, 719. Hebrew.

PMID:
23330266
16.

Hepatitis C virus and lipids in the era of direct acting antivirals (DAAs).

Sheridan DA, Neely RD, Bassendine MF.

Clin Res Hepatol Gastroenterol. 2013 Feb;37(1):10-6. doi: 10.1016/j.clinre.2012.07.002. Epub 2012 Sep 5. Review.

PMID:
22959093
17.

Rapid progression of antiviral treatments of chronic hepatitis C virus infection.

Pol S, Corouge M, Mallet V, Sogni P.

Minerva Gastroenterol Dietol. 2013 Jun;59(2):161-72.

PMID:
23831907
18.

Treatment of chronic HCV genotype 1 coinfection.

Boesecke C, Rockstroh JK.

Curr HIV/AIDS Rep. 2015 Sep;12(3):326-35. doi: 10.1007/s11904-015-0278-4. Review.

PMID:
26228050
19.

Hepatitis C virus: standard-of-care treatment.

Pawlotsky JM.

Adv Pharmacol. 2013;67:169-215. doi: 10.1016/B978-0-12-405880-4.00005-6. Review.

PMID:
23886001
20.

Current progress in the treatment of chronic hepatitis C.

Alexopoulou A, Papatheodoridis GV.

World J Gastroenterol. 2012 Nov 14;18(42):6060-9. doi: 10.3748/wjg.v18.i42.6060. Review.

Supplemental Content

Support Center